DelveInsight reports that the Parkinson’s Disease pipeline includes over 130 key companies actively developing more than 150 therapeutic candidates.
Parkinson’s Disease Overview:
Parkinson’s disease (PD) is a chronic, progressive neurological disorder that primarily affects movement. It arises from the gradual loss of dopamine-producing neurons in the substantia nigra, a brain region critical for motor control. Although PD most commonly develops in individuals over 60, it can occasionally occur earlier. It is the second most common neurodegenerative disease after Alzheimer’s, and its progression varies widely among patients, making prediction and management challenging.
The primary motor symptoms of PD include tremors, slowed movement (bradykinesia), muscle stiffness (rigidity), and postural instability. Tremors usually begin in a single limb, often the hand or fingers, and are most noticeable at rest. Bradykinesia can significantly interfere with daily activities by slowing voluntary movements. Muscle rigidity leads to stiffness and limited motion, while postural instability increases the risk of falls. PD also presents with non-motor symptoms, including sleep disturbances, depression, anxiety, cognitive impairment, and autonomic nervous system dysfunction.
Download our report @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Parkinson’s Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson’s Disease Therapeutics Market.
Key Takeaways from the Parkinson’s Disease Pipeline Report
DelveInsight’s Parkinson’s Disease (PD) pipeline report highlights a vibrant landscape, with over 130 companies actively developing more than 150 therapeutic candidates.
Key regulatory updates include:
-
February 2025: The FDA approved Medtronic’s BrainSense Adaptive Deep Brain Stimulation (aDBS) system, which adjusts stimulation in real-time based on brain signals, offering more personalized symptom management compared to traditional continuous DBS devices.
-
February 4, 2025: The FDA approved Onapgo (apomorphine hydrochloride), a continuous subcutaneous infusion therapy for PD patients experiencing significant “off” episodes, when standard medications are less effective.
-
October 2024: The FDA approved Vyalev (foscarbidopa and foslevodopa), the first 24-hour subcutaneous continuous levodopa infusion for adults with advanced PD and motor fluctuations, providing consistent dopamine delivery for steady symptom control.
Leading companies developing PD therapies include Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences, Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron, Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune, and others.
Notable PD pipeline therapies in various stages of development include Buntanetap, Tavapadon, Prasinezumab, Risvodetinib, GT 02287, among several additional candidates.
Parkinson’s Disease Pipeline Analysis
The Parkinson’s Disease pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Parkinson’s Disease Market.
-
Categorizes Parkinson’s Disease therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Parkinson’s Disease drugs under development based on:
-
Stage of development
-
Parkinson’s Disease Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Parkinson’s Disease Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Parkinson’s Disease Licensing agreements
-
Funding and investment activities supporting future Parkinson’s Disease market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Parkinson’s Disease Emerging Drugs
-
Buntanetap: Annovis Bio
-
Tavapadon: Cerevel Therapeutics
-
Prasinezumab: Roche
-
Risvodetinib: Inhibikase Therapeutics, Inc
-
GT 02287: Gain Therapeutics
-
NNI 362: Neuronascent
Parkinson’s Disease Companies
More than 130 leading companies are actively developing therapies for Parkinson’s disease, with Annovis Bio advancing a drug candidate to the most advanced stage—Phase III clinical trials.
DelveInsight’s report covers around 150+ products under different phases of Parkinson’s Disease clinical trials like
-
Parkinson’s Disease Late stage Therapies (Phase III)
-
Parkinson’s Disease Mid-stage Therapies (Phase II)
-
Parkinson’s Disease Early-stage Therapies (Phase I)
-
Parkinson’s Disease Pre-clinical and Parkinson’s Disease Discovery stage Therapies
-
Parkinson’s Disease Discontinued & Inactive Therapies
Parkinson’s Disease pipeline report provides the Parkinson’s Disease therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Parkinson’s Disease Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson’s Disease Therapies and Key Parkinson’s Disease Companies: Parkinson’s Disease Clinical Trials and recent advancements
Parkinson’s Disease Pipeline Therapeutic Assessment
• Parkinson’s Disease Assessment by Product Type
• Parkinson’s Disease By Stage
• Parkinson’s Disease Assessment by Route of Administration
• Parkinson’s Disease Assessment by Molecule Type
Download Parkinson’s Disease Sample report to know in detail about the Parkinson’s Disease treatment market @ Parkinson’s Disease Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Parkinson’s Disease Current Treatment Patterns
4. Parkinson’s Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parkinson’s Disease Late-Stage Products (Phase-III)
7. Parkinson’s Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parkinson’s Disease Discontinued Products
13. Parkinson’s Disease Product Profiles
14. Parkinson’s Disease Key Companies
15. Parkinson’s Disease Key Products
16. Dormant and Discontinued Products
17. Parkinson’s Disease Unmet Needs
18. Parkinson’s Disease Future Perspectives
19. Parkinson’s Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Parkinson’s Disease Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
